| Idiopathic Pulmonary Fibrosis |
1 |
1 |
| Lung Fibrosis |
0 |
0.88 |
| Lung |
0 |
0.69 |
| Interstitial Lung Disease |
0 |
0.63 |
| Healthcare and Medical Technology |
0 |
0.37 |
| Biomarker |
0 |
0.34 |
| CT Scan |
0 |
0.29 |
| Artificial Intelligence |
0 |
0.21 |
| Clinical Guidelines |
0 |
0.21 |
| Biopsy |
0 |
0.14 |
| Blood |
0 |
0.14 |
| Proteomics |
0 |
0.14 |
| Stress |
0 |
0.14 |
| Anxiety Disorder |
0 |
0.12 |
| Asthma |
0 |
0.12 |
| Cardiovascular Risk Management |
0 |
0.12 |
| Care and Maintenance of Vision |
0 |
0.12 |
| Cataract |
0 |
0.12 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.12 |
| Pneumonia |
0 |
0.12 |
| A-Scan Biometry |
0 |
0.07 |
| Anxiety |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| New York |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Pulmonary Function Test |
0 |
0.07 |
| Referral |
0 |
0.07 |
| Scan |
0 |
0.07 |
| UK Site Content |
0 |
0.07 |
| X-ray |
0 |
0.07 |